SCHEMBL6870570

SCHEMBL6870570

N#Cc1cc2c(c3cccc(O)c13)OCc1ccccc1-2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 2/20 0.34
RAB9A P51151 1/20 0.34
MAOB P27338 2/20 0.33
MAOA P21397 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
PGR P06401 2/20 0.33
KMT2A Q03164 1/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA4 P22748 2/20 0.32
CA6 P23280 2/20 0.32
MCL1 Q07820 1/20 0.32
USP8 P40818 1/20 0.31
USP7 Q93009 1/20 0.31
ESR2 Q92731 1/20 0.31
AURKA O14965 1/20 0.30
CDK1 P06493 1/20 0.30
CDK4 P11802 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924752 0.86 AR (0.34) ARMAPTALDH1A1RAB9AMAOB
SCHEMBL4450109 0.72 ESR1 (0.43) ARMAPKAPK2ESR2NOTUM
SCHEMBL31729511 0.71 MAOB (0.48) ARMAPTALDH1A1RAB9AMAOB
SCHEMBL3934285 0.70 ESR1 (0.36) MAPTALDH1A1RAB9ACA1CA2
SCHEMBL3929494 0.68 ESR1 (0.35) MAPTALDH1A1RAB9AMAOBMAOA
SCHEMBL3840410 0.68 ESR1 (0.41) ARCA1CA2CA4CA6
SCHEMBL3384063 0.68 ESR1 (0.39) ARESR2
SCHEMBL29384472 0.68 ESR1 (0.39) ARESR2
SCHEMBL13960113 0.66 ESR1 (0.36) MAPTALDH1A1RAB9AMAOBMAOA
SCHEMBL3180337 0.65 MAPT (0.50) ARMAPTALDH1A1MAOAPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6723747-B2 ESTROGEN RECEPTOR MODULATORS USEFUL IN TREATING OR INHIBITING CONDITIONS, DISORDERS, OR DISEASE STATES AT LEAST PARTIALLY MEDIATED BY ESTROGEN DEFICIENCY OR EXCESS, OR WHICH MAY BE TREATED OR INHIBITED THROUGH USE OF ESTROGENIC AGENT WYETH 2004-04-20 US disclosed
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents WYETH 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents ESR2, ESR1, ESRRA AR 13/4885MAPT 4552/4885ALDH1A1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.